Gliclazide, sold under the brand name Diamicron among others, is a sulfonylurea type of anti-diabetic medication, used to treat type 2 diabetes. It is used when dietary changes, exercise, and weight loss are not enough. It is taken by mouth.
Side effect may include low blood sugar, vomiting, abdominal pain, rash, and liver problems. Use by those with significant kidney problems or liver problems or who are pregnant is not recommended. Gliclazide is in the sulfonylurea family of medications. It works mostly by increasing the release of insulin.
Gliclazide was patented in 1966 and approved for medical use in 1972. It is on the World Health Organization's List of Essential Medicines. It is not available for sale in the United States.
|
Read full article at Wikipedia
|
InChI=1S/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19) |
BOVGTQGAOIONJV-UHFFFAOYSA-N |
Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CC2CCCC2C1 |
|
radical scavenger
A role played by a substance that can react readily with, and thereby eliminate, radicals.
|
|
insulin secretagogue
A secretagogue that causes the secretion of insulin.
|
|
hypoglycemic agent
A drug which lowers the blood glucose level.
|
|
View more via ChEBI Ontology
N-(hexahydrocyclopenta[c]pyrrol-2(1H)-ylcarbamoyl)-4-methylbenzenesulfonamide
|
1-(3-azabicyclo(3.3.0)oct-3-yl)-3-(p-tolylsulfonyl)urea
|
ChemIDplus
|
1-(hexahydrocyclopenta(c)pyrrol-2(1H)-yl)-3-(p-tolylsulfonyl)urea
|
ChemIDplus
|
Gliclazide
|
ChemIDplus
|
Glimicron
|
ChemIDplus
|
1657836
|
Reaxys Registry Number
|
Reaxys
|
21187-98-4
|
CAS Registry Number
|
ChemIDplus
|
21187-98-4
|
CAS Registry Number
|
KEGG DRUG
|
10048179
|
PubMed citation
|
Europe PMC
|
14871415
|
PubMed citation
|
Europe PMC
|
16631804
|
PubMed citation
|
Europe PMC
|
22118706
|
PubMed citation
|
Europe PMC
|
22183301
|
PubMed citation
|
Europe PMC
|
22411174
|
PubMed citation
|
Europe PMC
|
22732450
|
PubMed citation
|
Europe PMC
|
9226746
|
PubMed citation
|
Europe PMC
|
|